Instil Bio, Inc., a US headquartered cell therapy company focused on solid tumors, is currently rapidly expanding its infrastructure in Manchester, U.K. via its subsidiary, Instil Bio (UK) Ltd.
Instil Bio is developing patient specific immunotherapies in oncology, allowing the patient’s own immune system to be harnessed to fight cancer. The world renowned team and it’s scientific advisors/investors have tremendous experience and track record in technology discovery, process development, GMP manufacturing and clinical operations with a track record of developing and gaining approval for successful cell therapies.
Recent significant investments in Instil Bio are enabling the company to undertake Phase 2/3 to registrational clinical trials in solid tumors. Instil Bio (UK) is located between the University of Manchester and the main hospital campus, and is set to grow significantly in several key areas (GMP Manufacturing, Quality, Process Development, Support and Admin) to support these objectives.
48 Grafton St
Website: Instil Bio (UK)